Post-transplant malignancy is recognised as being a major limitation to the success of solid
organ transplantation and it is currently considered one of the unavoidable costs of long …

Introduction: The mTOR (mechanistic target of rapamycin, formerly known as mammalian
target of rapamycin) kinase is centrally involved in the regulation of cell growth and …

Background. The efficacy and safety of converting maintenance renal transplant recipients
from calcineurin inhibitors (CNIs) to sirolimus (SRL) was evaluated. Methods. Eight hundred …

Background: The calcineurin inhibitors (CNIs), cyclosporine and tacrolimus, have had a
revolutionary effect on the overall success of renal transplantation through reduction in early …

Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that inhibits cell cycle
progression and has proven to be a potent immunosuppressive agent for use in solid organ …

Proteinuria is associated with reduced kidney allograft survival. Herein we assessed the
association between proteinuria, graft histology and survival. The cohort included 613 …

Introduction: Mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus)
are a class of immunosuppressive drugs approved for solid organ transplantation (SOT). By …

As part of the Spare-the-Nephron trial, we evaluated the combination mycophenolate mofetil
(MMF) and sirolimus (SRL) as a calcineurin inhibitor (CNI)-free regimen for the preservation …

Sirolimus has been associated with high-range proteinuria when used in replacement of
calcineurin inhibitors in renal transplant recipients with chronic allograft nephropathy (CAN) …

Podocytes play a key role in maintaining the blood–urine barrier for high-molecular-weight
proteins. They are considered to be terminally differentiated, and podocyte loss cannot be …